Exercise capacity and brain natruiretic peptide in hypertension

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 4, 2002, Pages 519-527

  Lim, Pitt O ^a   Donnan, Peter T ^a   Struthers, Allan D ^a   MacDonald, Thomas M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

BNP; Exercise; Hypertension; Left Ventricular Hypertrophy

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE OXYGEN CONSUMPTION; HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MULTIPLE REGRESSION; MYOCARDIAL DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TIME;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PULMONARY VENTILATION; REGRESSION ANALYSIS; SEX FACTORS;

EID: 0036784892     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200210000-00004     Document Type: Article

References (32)

1. Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation 1997;96:741-7.
2. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-80.
3. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
4. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.
5. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999;10:537-40.
6. Yamamoto K, Burnett JC, Jr., Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
7. Kario K, Nishikimi T, Yoshihara F, et al. Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 h blood pressure. J Hypertens 1998;16:1253-9.
8. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
9. Opie LH. Mechanism of Cardiac Contraction and relaxation. In: Braunwald E, ed. Heart Disease: a textbook of cardiovascular medicine, philadelphia: W. B. Saunders, 1997:360-393.
10. Lim PO, MacFadyen RJ, Clarkson PB, MacDonald TM. Impaired exercise tolerance in hypertensive patients. Ann Intern Med 1996;124:41-55.
11. Clarkson PB, Wheeldon NM, MacFadyen RJ, Pringle SD, MacDonald TM. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996;93:2037-42.
12. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995;98:257-65.
13. La Villa G, Vena S, Conti A, et al. Plasma levels of brain natriuretic peptide in healthy subjects and patients with essential hypertension: response to posture. Clin Sci (Colch) 1993;85:411-6.
14. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000;35:844-51.
15. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.
16. Wasserman K, Hansen J, E., Sue DY, Whipp BJ. Normal values. In: Wasserman K, Hansen J, E., Sue DY, Whipp BJ, eds. Principles of Exercise Testing and Interpretation. Philadelphia: Lea & febiger, 1987:72-85.
17. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020-7.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
19. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
20. Hammond IW, Devereux RB, Alderman MH, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among used patients with uncomplicated hypertension. J Am Coll Cardiol 1986;7:639-50.
21. Clarkson PB, Wheeldon NM, Macleod C, Coutie W, MacDonald TM. Acute effects of atrial natriuretic peptide on left ventricular diastolic function, a pulsed wave Doppler study in man. Eur Heart J 1995;16:1710-15.
22. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-7.
23. Pidgeon GB, Richards AM, Nicholls MG, Espiner EA, Yandle TG, Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension 1996;27:906-13.
24. La Villa G, Bisi G, Lazzeri C, et al. Cardiovascular effects of brain natriuretic peptide in essential hypertension. Hypertension 1995;25:1053-7.
25. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
26. Tanaka M, Ishizaka Y, Ishiyama Y, et al. Exercise-induced secretion of brain natriuretic peptide in essential hypertension and normal subjects. Hypertens Res 1995;18:159-66.
27. Nishikimi T, Morimoto A, Ishikawa K, et al. Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects. Clin Exp Hypertens 1997;19:503-18.
28. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081-8.
29. Kohno M, Yasunari K, Yokokawa K, et al. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy. Metabolism 1996;45:1326-9.
30. Thomas CJ, Head GA, Woods RL. Similar baroreflex bradycardic actions of atrial natriuretic peptide and B and C types of natriuretic peptides in conscious rats. J Hypertens 1999;17:801-6.
31. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 1999;12:921-4.
32. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000;83:278-82.